9/4/12 AlloCure Begins Phase 2 Clinical Trial in Acute Kidney Injury

4/2/12 AlloCure Raises $25 Million Series B Venture Financing

1/5/12 AlloCure's Investigational Treatment for Acute Kidney Injury Receives Fast Track Designation by FDA

11/14/11 AlloCure Presents Safety and Preliminary Efficacy of AC607 for the Treatment of Acute Kidney Injury at ASN

AlloCure, Inc. is a pioneer in the development of cell therapies for the treatment of kidney disease and is a leader in the acute kidney injury field. The company's proprietary technology enables the isolation and expansion of mesenchymal stem cells (MSC), obtained via conventional bone marrow donation, which can then be administered off-the-shelf to any patient in need without requiring tissue matching or immunosuppressants.

The company's most advanced program, AC607, targeting acute kidney injury, has entered phase 2 clinical development with the initiation of ACT-AKI (AC607 Trial in Acute Kidney Injury), and represents the first cell therapy to treat this potentially life threatening condition. For more information click on the trial logo.